Cargando…

Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature

BACKGROUND: A growing number of studies have demonstrated that immune-related long noncoding ribonucleic acids (irlncRNAs) are potential prognostic factors for lung adenocarcinoma. Two-gene combination patterns could improve the sensitivity of prognostic models, providing us a novel signature constr...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Xiangjun, Chen, Guoming, Chen, Zhuangzhong, Li, Jing, Chen, Wenmin, Lin, Jietao, Lin, Lizhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371455/
https://www.ncbi.nlm.nih.gov/pubmed/34421308
http://dx.doi.org/10.2147/IJGM.S325240
_version_ 1783739645682515968
author Qi, Xiangjun
Chen, Guoming
Chen, Zhuangzhong
Li, Jing
Chen, Wenmin
Lin, Jietao
Lin, Lizhu
author_facet Qi, Xiangjun
Chen, Guoming
Chen, Zhuangzhong
Li, Jing
Chen, Wenmin
Lin, Jietao
Lin, Lizhu
author_sort Qi, Xiangjun
collection PubMed
description BACKGROUND: A growing number of studies have demonstrated that immune-related long noncoding ribonucleic acids (irlncRNAs) are potential prognostic factors for lung adenocarcinoma. Two-gene combination patterns could improve the sensitivity of prognostic models, providing us a novel signature construction concept that we applied to lung adenocarcinoma. METHODS: Gene expression and clinical data were downloaded from the Lung Adenocarcinoma project of The Cancer Genome Atlas (TCGA) database. We applied a co-expression analysis with immune genes obtained from the ImmPort database to recognize irlncRNA. The matrix of irlncRNA pairs was established by a cyclic comparison of each lncRNA pair expression level. Univariate and multivariate Cox regressions and Lasso penalized regression analysis were applied to construct the risk model. Patients with lung adenocarcinoma were divided into high- and low-risk groups, according to the Akaike Information Criterion (AIC) values of the receiver operating characteristic (ROC) curve. Then, we evaluated our signature under various clinical settings: clinical-pathological characteristics, tumor-infiltrating immune cells, checkpoint-related biomarkers, targeted therapy, and chemotherapy. RESULTS: Based on the 239 differently expressed irlncRNAs, we constructed an 11-irlncRNA pair signature. The area under the curve (AUC) of the ROC curve for the signature to predict the 4-year survival rate was 0.819, and the cut-off point was recognized as 1.003. Subsequent analysis showed that our signature can effectively distinguish unfavorable survival outcomes, prognostic clinic-pathological characteristics, and specify tumor infiltration status. Highly expressed immune checkpoint-related genes, as well as higher chemosensitivity, were correlated to the low-risk group. CONCLUSION: We constructed a novel lung adenocarcinoma irlncRNA signature with promising prognostic value using the TCGA database, based on paired irlncRNAs and not relying on lncRNAs special expression levels.
format Online
Article
Text
id pubmed-8371455
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83714552021-08-19 Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature Qi, Xiangjun Chen, Guoming Chen, Zhuangzhong Li, Jing Chen, Wenmin Lin, Jietao Lin, Lizhu Int J Gen Med Original Research BACKGROUND: A growing number of studies have demonstrated that immune-related long noncoding ribonucleic acids (irlncRNAs) are potential prognostic factors for lung adenocarcinoma. Two-gene combination patterns could improve the sensitivity of prognostic models, providing us a novel signature construction concept that we applied to lung adenocarcinoma. METHODS: Gene expression and clinical data were downloaded from the Lung Adenocarcinoma project of The Cancer Genome Atlas (TCGA) database. We applied a co-expression analysis with immune genes obtained from the ImmPort database to recognize irlncRNA. The matrix of irlncRNA pairs was established by a cyclic comparison of each lncRNA pair expression level. Univariate and multivariate Cox regressions and Lasso penalized regression analysis were applied to construct the risk model. Patients with lung adenocarcinoma were divided into high- and low-risk groups, according to the Akaike Information Criterion (AIC) values of the receiver operating characteristic (ROC) curve. Then, we evaluated our signature under various clinical settings: clinical-pathological characteristics, tumor-infiltrating immune cells, checkpoint-related biomarkers, targeted therapy, and chemotherapy. RESULTS: Based on the 239 differently expressed irlncRNAs, we constructed an 11-irlncRNA pair signature. The area under the curve (AUC) of the ROC curve for the signature to predict the 4-year survival rate was 0.819, and the cut-off point was recognized as 1.003. Subsequent analysis showed that our signature can effectively distinguish unfavorable survival outcomes, prognostic clinic-pathological characteristics, and specify tumor infiltration status. Highly expressed immune checkpoint-related genes, as well as higher chemosensitivity, were correlated to the low-risk group. CONCLUSION: We constructed a novel lung adenocarcinoma irlncRNA signature with promising prognostic value using the TCGA database, based on paired irlncRNAs and not relying on lncRNAs special expression levels. Dove 2021-08-11 /pmc/articles/PMC8371455/ /pubmed/34421308 http://dx.doi.org/10.2147/IJGM.S325240 Text en © 2021 Qi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Qi, Xiangjun
Chen, Guoming
Chen, Zhuangzhong
Li, Jing
Chen, Wenmin
Lin, Jietao
Lin, Lizhu
Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature
title Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature
title_full Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature
title_fullStr Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature
title_full_unstemmed Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature
title_short Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature
title_sort construction of a novel lung adenocarcinoma immune-related lncrna pair signature
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371455/
https://www.ncbi.nlm.nih.gov/pubmed/34421308
http://dx.doi.org/10.2147/IJGM.S325240
work_keys_str_mv AT qixiangjun constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature
AT chenguoming constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature
AT chenzhuangzhong constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature
AT lijing constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature
AT chenwenmin constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature
AT linjietao constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature
AT linlizhu constructionofanovellungadenocarcinomaimmunerelatedlncrnapairsignature